Loading organizations...

§ Private Profile · Marseille, Provence-Alpes-Cote d'Azur, France
Volta Medical is a technology company.
Volta Medical develops AI-powered solutions for cardiac electrophysiology. Its core product, Volta AF-Xplorer™ II, is an AI Companion Technology for precise Atrial Fibrillation (AF) and Atrial Tachycardia (AT) assessment. The system uses artificial intelligence to analyze real-time intracardiac atrial electrograms, pinpointing critical areas driving arrhythmia mechanisms via its proprietary VoltaPlex data ecosystem.
Founded in 2016, Volta Medical arose from cardiologists Dr. Julien Seitz, Dr. Clément Bars, Dr. Jérôme Kalifa, and data scientist Théophile Mohr Durdez. They identified a need to overcome inconsistencies in complex AF ablation by leveraging AI. Their vision was to reproduce detailed electrophysiologist analysis via machine learning, thereby standardizing arrhythmia treatment.
Electrophysiologists utilize Volta Medical’s technology to guide cardiac ablation procedures, enhancing arrhythmia substrate identification and targeting. The company's mission centers on improving the assessment and treatment of complex heart rhythm pathologies. By delivering objective, AI-driven insights, Volta Medical aims to elevate interventional electrophysiology success, transforming patient outcomes.
Volta Medical has raised $66.0M across 2 funding rounds.
Volta Medical has raised $66.0M in total across 2 funding rounds.
Volta Medical is a French healthtech company founded in 2016 that develops AI software solutions to assist cardiac electrophysiologists during arrhythmia treatment procedures, particularly for complex cases like persistent atrial fibrillation (AFib).[1][2][3] Its flagship products, including the FDA-cleared and CE-marked Volta AF-Xplorer and the newly launched Volta AF-Xplorer II, provide real-time identification of abnormal electrograms (EGMs) to improve ablation precision, reduce repeat procedures, and enhance patient outcomes for millions affected by AFib.[1][2][4][5] Serving electrophysiologists in hospitals across the US and Europe, Volta addresses the challenge of inconsistent AFib ablation results by leveraging data-driven AI trained on large procedural databases, with over €90 million raised to fuel R&D, commercialization, and US expansion.[1][3]
The company solves a critical gap in cardiac electrophysiology: detecting spatio-temporal dispersed EGMs that drive AFib recurrence, which traditional methods often miss, leading to high failure rates in repeat ablations.[2][5] Growth momentum is strong, marked by FDA 510(k) clearance in 2020, positive TAILORED-AF trial results published in *Nature Medicine* showing superior freedom from AF, ongoing RESTART trial for recurrent cases, early US commercialization (e.g., at Ochsner Health), and a joint development agreement with GE Healthcare.[1][2][5][6]
Volta Medical emerged in Marseille, France, in 2016 from a collaboration between three cardiologists and a data scientist from École Polytechnique, driven by frustrations in treating complex arrhythmias like AFib during catheter ablations.[2][3][5] The founders recognized that manual analysis of 3D heart maps and EGMs was inconsistent and time-intensive, inspiring AI tools trained on vast procedural datasets to automate detection of AFib drivers.[1][2] Early traction came swiftly: Gilde Healthcare invested in 2020 to support FDA clearance for VX1 (now evolved into AF-Xplorer), enabling US and European rollouts as the first AI in interventional electrophysiology.[1] Pivotal moments include the 2024 HRS presentation of TAILORED-AF results and the recent US launch of AF-Xplorer II, alongside building a 31-person US team blending French and American expertise.[2][3][4]
Volta rides the AI-in-healthcare wave, specifically transforming electrophysiology amid rising AFib prevalence (affecting millions) and demand for precision medicine in an aging population.[1][5] Timing is ideal post-2020 FDA milestone, aligning with AI regulatory momentum and post-pandemic focus on efficient cardiac interventions that cut costs from repeat procedures.[1][2] Market forces like exploding procedural data volumes and partnerships (e.g., GE Healthcare) favor Volta, positioning it to standardize AI-guided ablations and influence EP workflows globally.[2][4] By publishing landmark trials in *Nature Medicine* and expanding commercially, Volta shapes the ecosystem, inspiring data-driven medtech and reducing healthcare burdens through better outcomes.[2][5][6]
Volta Medical is poised to redefine AFib treatment as AI becomes the new standard in EP, with AF-Xplorer II driving US adoption and RESTART trial results potentially unlocking recurrent-AF markets.[2][4][6] Expect accelerated growth via GE collaboration, further trials, and international scaling, fueled by €90M+ funding and trial successes amid AI-health booms.[3] Trends like multimodal AI integration and value-based care will amplify its edge, evolving Volta from pioneer to category leader—potentially slashing global repeat ablations and affirming its mission to transform cardiac care from day one.[1][2]
Volta Medical has raised $66.0M in total across 2 funding rounds.
Volta Medical's investors include Vensana Capital, Northpond Ventures, Lightstone Ventures, Pasteur Mutualit.
Volta Medical has raised $66.0M across 2 funding rounds. Most recently, it raised $38.0M Series B in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2023 | $38M Series B | Vensana Capital | Northpond Ventures, Lightstone Ventures | Announced |
| Jan 5, 2021 | $28M Venture Round | — | Pasteur Mutualit | Announced |